Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2020-11-05 Earnings Release
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 5, 2020, reporting the company's financial results and business highlights for the quarter ended September 30, 2020. It specifically mentions that a press release announcing these results is furnished as an exhibit. The document itself is a current report filing, not the full quarterly or annual report. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document length is 3342 characters, which is typical for an 8-K earnings release announcement. Therefore, the appropriate classification is Earnings Release (ER).
2020-11-05 English
FORM 3
Director's Dealing
2020-11-03 English
Regulatory Filings 2020
Regulatory Filings
2020-10-27 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal correspondence related to a securities registration filing, specifically a request for the SEC to declare the registration statement effective by a certain date and time. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory filing related to the registration process rather than a financial report or announcement of results. The length is short (1503 characters), and it is clearly a formal request letter, not a report or presentation. Therefore, it fits best under Regulatory Filings (RNS).
2020-10-22 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, form names, fiscal period dates, or document titles that would allow identification of a specific filing type. The text is approximately 15,000 characters long, which is substantial, but without any meaningful content or context, it is impossible to classify it as a specific report or announcement. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a general category for filings that do not fit into other specific categories.
2020-10-21 English
FORM 4
Director's Dealing
2020-10-21 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.